AGILeBiotics is developing novel next-generation aminoglycoside antibiotics for the treatment of multi-drug resistant (MDR) Gram-negative infections associated to high death rates, i.e. hospital-acquired-/ventilator-associated pneumonia (HAP/VAP), bloodstream infections (BSI) and neonatal sepsis. Our main focus is to find new antibiotic candidates active against carbepenem-resistant Enterobacteriaceae (CRE). In addition, AGILeBiotics is motivated to find novel treatment options for MDR tuberculosis and cystic fibrosis.
